PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of Px Wire.
Px Wire July-September 2022, Vol. 12, No. 2
Cost of Goods Sold (COGS) Analyses
FAQ Debrief
This FAQ explains the use of Cost of Good Sold Analyses (COGS) and how they inform planning for product introduction.
Access to the Dapivirine Vaginal Ring: A timeline on progress
Global Fund Investment Case: Seventh replenishment 2022 executive summary
The Global Fund’s analysis of the economic case for increased investment and commitment to its strategy pandemic preparedness and ending HIV, TB and malaria.
Global Fund Key Numbers and Messages
Key messages and numbers to advocate for full funding of the Global Fund.
ViiV’s Community Stakeholder Engagement Strategy for Low- and Middle-Income Countries (2022-2024)
ViiV’s 2022-2024 strategy for community stakeholder engagement in low and middle income countries pledges a commitment to Good Participatory Practice Guidelines and more.
Px Wire April-June 2022, Vol. 12, No. 1
Newly relaunched, PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Download for a quick look at where we are in HIV prevention.
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP (Summary)
AVAC published Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP to provide a comprehensive view of all the moving parts and identify specific priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered in introducing injectable cabotegravir for PrEP. ViiV, policy makers, normative agencies, donors, program implementers, researchers, generic manufacturers, civil society, advocates and communities each have critical roles to play in the coming months, and this summary provides an overview of the plan.
CAB-LA Trials at a Glance
This infographic shares a breakdown of the current injectable CAB for PrEP trials including ongoing sub-studies.
Research Fundamentals: An HIV Vaccine — What’s the challenge and what’s the science?
Some vaccines are easier to develop than others. COVID-19 vaccines were developed with unprecedented speed, taking a matter of months to become available. A measles vaccine took about 10 years to develop. But the field’s been working on an HIV vaccine for 40 years.
In this episode, AVAC’s Jeanne Baron and co-host immunologist Katharine Kripke of AVENIR Health explore why HIV is different with two experts on vaccine research: Caltech’s Pamela Bjorkman and IAVI’s Vincent Kioi.
Learn how HIV has evolved like no other virus today to escape detection by the immune system. Learn why the right target on HIV is so hard to reach and how scientists are tackling it all.